ATE531701T1 - Neue quaternüre ammoniumverbindungen - Google Patents
Neue quaternüre ammoniumverbindungenInfo
- Publication number
- ATE531701T1 ATE531701T1 AT03791398T AT03791398T ATE531701T1 AT E531701 T1 ATE531701 T1 AT E531701T1 AT 03791398 T AT03791398 T AT 03791398T AT 03791398 T AT03791398 T AT 03791398T AT E531701 T1 ATE531701 T1 AT E531701T1
- Authority
- AT
- Austria
- Prior art keywords
- prevention
- treatment
- drugs
- quaternure
- new
- Prior art date
Links
- 150000003868 ammonium compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 4
- 230000002265 prevention Effects 0.000 abstract 4
- 206010008635 Cholestasis Diseases 0.000 abstract 2
- 208000004930 Fatty Liver Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 208000019423 liver disease Diseases 0.000 abstract 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 abstract 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 abstract 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 abstract 1
- 150000007657 benzothiazepines Chemical class 0.000 abstract 1
- 108091022863 bile acid binding Proteins 0.000 abstract 1
- 102000030904 bile acid binding Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 abstract 1
- 208000010157 sclerosing cholangitis Diseases 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002248586 | 2002-08-28 | ||
| JP2002364725 | 2002-12-17 | ||
| PCT/JP2003/010980 WO2004020421A1 (ja) | 2002-08-28 | 2003-08-28 | 新規な４級アンモニウム化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE531701T1 true ATE531701T1 (de) | 2011-11-15 |
Family
ID=31980497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03791398T ATE531701T1 (de) | 2002-08-28 | 2003-08-28 | Neue quaternüre ammoniumverbindungen |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1535913B1 (de) |
| JP (1) | JP4497472B2 (de) |
| KR (1) | KR100990524B1 (de) |
| CN (1) | CN100494185C (de) |
| AT (1) | ATE531701T1 (de) |
| AU (1) | AU2003257578B2 (de) |
| CA (1) | CA2497345C (de) |
| WO (1) | WO2004020421A1 (de) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070026392A (ko) | 2004-02-27 | 2007-03-08 | 아사히 가세이 파마 가부시키가이샤 | 신규 벤조티아제핀 및 벤조티에핀 화합물 |
| FI20055503A0 (fi) * | 2005-09-20 | 2005-09-20 | Fennopharma Oy | Uudet kvaternääriset polymeerit |
| WO2010062861A2 (en) * | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
| ES2687027T3 (es) | 2010-11-04 | 2018-10-23 | Albireo Ab | Inhibidores de ibat para el tratamiento de enfermedades hepáticas |
| DK2637646T3 (en) * | 2010-11-08 | 2016-08-29 | Albireo Ab | PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder |
| WO2012064268A1 (en) * | 2010-11-08 | 2012-05-18 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
| US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
| AU2012328526B2 (en) * | 2011-10-28 | 2017-05-25 | Shire Human Genetic Therapies, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| WO2014071182A1 (en) | 2012-11-01 | 2014-05-08 | Massachusetts Institute Of Technology | Directed evolution of synthetic gene cluster |
| CA2907230A1 (en) * | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| EP3012252A1 (de) | 2014-10-24 | 2016-04-27 | Ferring BV | Kristalline Form von elobixibat |
| KR102804055B1 (ko) | 2015-07-13 | 2025-05-08 | 피벗 바이오, 인크. | 식물 형질 개선을 위한 방법 및 조성물 |
| CA3001001A1 (en) | 2015-10-05 | 2017-04-13 | Massachusetts Institute Of Technology | Nitrogen fixation using refactored nif clusters |
| CN108601739B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 考来烯胺丸剂及其制备方法 |
| WO2017138878A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
| CN116904333A (zh) | 2017-01-12 | 2023-10-20 | 皮沃特生物公司 | 用于改良植物性状的方法及组合物 |
| US10858351B2 (en) * | 2017-04-26 | 2020-12-08 | Alberta Research Chemicals Inc. | Substituted tetrahydropyridine derivatives as IDO-1 inhibitors and uses thereof |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| EP3664782B1 (de) | 2017-08-09 | 2025-01-29 | Albireo AB | Cholestyraminpellets, orale cholestyraminformulierungen und ihre medizinische verwendung |
| CN111527057A (zh) | 2017-10-25 | 2020-08-11 | 皮沃特生物股份有限公司 | 靶向改良植物性状的固氮的基因靶标 |
| MX2020004343A (es) | 2017-10-25 | 2021-01-08 | Pivot Bio Inc | Métodos y composiciones para mejorar microbios modificados que fijan nitrógeno. |
| CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| PL3810581T3 (pl) | 2018-06-20 | 2025-04-28 | Albireo Ab | Modyfikacje kryształu odewiksibatu |
| EP3813511A4 (de) | 2018-06-27 | 2022-08-03 | Pivot Bio, Inc. | Geführte mikrobielle remodellierung, plattform zur rationellen verbesserung mikrobieller spezies für die landwirtschaft |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| CN118852054A (zh) | 2019-02-06 | 2024-10-29 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| TWI835997B (zh) | 2019-02-06 | 2024-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其用作膽酸調節劑之用途 |
| WO2020190363A1 (en) | 2019-03-19 | 2020-09-24 | Massachusetts Institute Of Technology | Control of nitrogen fixation in rhizobia that associate with cereals |
| CA3129539A1 (en) | 2019-04-25 | 2020-10-29 | Min-Hyung RYU | High-throughput methods for isolating and characterizing ammonium-excreting mutant libraries generated by chemical mutagenesis |
| JP7696898B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| AR120676A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
| IL293379B2 (en) | 2019-12-04 | 2026-04-01 | Albireo Ab | Benzothia(dia)azepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| EP4069247B1 (de) | 2019-12-04 | 2025-03-26 | Albireo AB | Benzothiadiazepinverbindungen und ihre verwendung als gallensäuremodulatoren |
| WO2021110883A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2021110884A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TWI877263B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| AU2020445067A1 (en) | 2020-05-01 | 2022-12-01 | Pivot Bio, Inc. | Measurement of nitrogen fixation and incorporation |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4188541B1 (de) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepin-verbindungen und ihre verwendung als gallensäuremodulatoren |
| CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| EP4511038A1 (de) | 2022-04-22 | 2025-02-26 | Albireo AB | Subkutane verabreichung eines asbt-hemmers |
| KR20250022025A (ko) | 2022-06-09 | 2025-02-14 | 알비레오 에이비 | 간염 치료 |
| CN119487013A (zh) | 2022-07-05 | 2025-02-18 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| AU2023390975A1 (en) | 2022-12-09 | 2025-06-05 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL108634A0 (en) * | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| ZA941003B (en) * | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
| US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| HUP9903047A3 (en) * | 1996-03-11 | 2002-12-28 | G D Searle & Co Chicago | Novel benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| PL336415A1 (en) * | 1997-03-11 | 2000-06-19 | Searle & Co | Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors |
| GB9821296D0 (en) * | 1998-10-01 | 1998-11-25 | Zeneca Ltd | Composition |
| JP2002536440A (ja) * | 1999-02-12 | 2002-10-29 | ジー．ディー．サール エルエルシー | 回腸胆汁酸輸送およびタウロコール酸塩取り込みの阻害剤としての活性を有する新規１，２−ベンゾチアゼピン |
| DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| US20020183307A1 (en) * | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| WO2002053548A1 (fr) * | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Derives de la benzothiazepine |
-
2003
- 2003-08-28 CN CNB038207117A patent/CN100494185C/zh not_active Expired - Fee Related
- 2003-08-28 AT AT03791398T patent/ATE531701T1/de active
- 2003-08-28 JP JP2004532766A patent/JP4497472B2/ja not_active Expired - Fee Related
- 2003-08-28 KR KR1020057003204A patent/KR100990524B1/ko not_active Expired - Fee Related
- 2003-08-28 AU AU2003257578A patent/AU2003257578B2/en not_active Ceased
- 2003-08-28 CA CA002497345A patent/CA2497345C/en not_active Expired - Fee Related
- 2003-08-28 WO PCT/JP2003/010980 patent/WO2004020421A1/ja not_active Ceased
- 2003-08-28 EP EP03791398A patent/EP1535913B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2497345A1 (en) | 2004-03-11 |
| CA2497345C (en) | 2008-10-14 |
| AU2003257578B2 (en) | 2009-01-22 |
| EP1535913B1 (de) | 2011-11-02 |
| EP1535913A4 (de) | 2008-04-09 |
| CN100494185C (zh) | 2009-06-03 |
| KR20050059088A (ko) | 2005-06-17 |
| KR100990524B1 (ko) | 2010-10-29 |
| JPWO2004020421A1 (ja) | 2005-12-15 |
| CN1678597A (zh) | 2005-10-05 |
| AU2003257578A1 (en) | 2004-03-19 |
| JP4497472B2 (ja) | 2010-07-07 |
| WO2004020421A1 (ja) | 2004-03-11 |
| EP1535913A1 (de) | 2005-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE531701T1 (de) | Neue quaternüre ammoniumverbindungen | |
| ATE555101T1 (de) | Neue benzothiazepin- und benzothiepinverbindungen | |
| ATE283266T1 (de) | 1,5-benzothiazepine und ihre verwendungs als hypolipidämika | |
| IS7170A (is) | Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra | |
| RU2002107975A (ru) | Глюкопиранозилоксипиразольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для их получения | |
| DE60233239D1 (de) | Benzothiazepinderivate | |
| HUP0200793A3 (en) | An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport | |
| IL187813A0 (en) | Pharmaceutical compositions of a neuroactive steroid and uses thereof | |
| WO2004016614A3 (en) | Pyrrolopyrazines as kinase inhibitors | |
| IL160690A0 (en) | Benzothiazepine ileal bile acid transport inhibitors | |
| NO20081074L (no) | Macrocyclisk inhibitorer av hepatitis C-virus | |
| ATE454379T1 (de) | Benzothiazepin-derivate für die behandlung von hyperlipidemia | |
| IT1311922B1 (it) | Composti farmaceutici. | |
| BRPI0610312B8 (pt) | dispositivo de assistência à caminhada | |
| DE60025616D1 (de) | Isoindolderivate | |
| TW200612920A (en) | Novel imidazolidine derivatives | |
| MXPA04003611A (es) | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
| BR0213465A (pt) | Compostos de 4-imidazolin-2-ona | |
| WO2007025897A3 (en) | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | |
| DK1750703T3 (da) | Fremgangsmåde til at reducere gastrointestinal toksitet forårsaget af indgivelsen af tegafur | |
| DK0988312T3 (da) | 17beta-allyloxy(thio)alkyl-androstanderivater til modulering af meiose | |
| WO2004054565A8 (en) | Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders | |
| ITMI20021881A1 (it) | Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario. | |
| TW200730498A (en) | Compounds | |
| DK1163258T3 (da) | Derivater af 22R-hydroxycholesta-8, 14-dien til inhiberingen af meiosis |